Trial Profile
A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2022
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GetGoal-O
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 11 Jan 2022 This trial has been completed in Norway, according to European Clinical Trials Database record. (19 Feb 2015)
- 19 Jun 2019 According to European Clinical Trials Database record, trial is completed at UK, Sweden, Spain,Germany,Bulgaria and Denmark locations (End date: 18 Feb 2015).
- 05 Oct 2018 Results of post-hoc subgroup analysis presented at the 54th Annual Meeting of the European Association for the Study of Diabetes.